Pyxis Oncology logo

Pyxis Oncology Share Price (NASDAQ: PYXS)

$1.29

-0.04

(-3.01%)

Last updated on

Check the interactive Pyxis Oncology Stock chart to analyse performance

Pyxis Oncology stock performance

as on August 30, 2025 at 1:29 am IST

  • Today's Low:$1.29
    Today's High:$1.33

    Day's Volatility :3.01%

  • 52 Weeks Low:$0.83
    52 Weeks High:$5.39

    52 Weeks Volatility :84.54%

Pyxis Oncology Stock Returns

PeriodPyxis Oncology, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
6.56%
3.6%
0.0%
6 Months
17.12%
-7.7%
0.0%
1 Year
-62.21%
-12.6%
0.0%
3 Years
-50.57%
9.5%
-4.7%

Pyxis Oncology, Inc. Key Stats

Check Pyxis Oncology key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$1.33
Open
$1.33
Today's High
$1.33
Today's Low
$1.29
Market Capitalization
$84.3M
Today's Volume
$153.4K
52 Week High
$5.3899
52 Week Low
$0.8332
Revenue TTM
$2.8M
EBITDA
$-80.5M
Earnings Per Share (EPS)
$-1.59
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-74.8%

Stock Returns calculator for Pyxis Oncology Stock including INR - Dollar returns

The Pyxis Oncology stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Pyxis Oncology investment value today

Current value as on today

₹39,321

Returns

₹60,679

(-60.68%)

Returns from Pyxis Oncology Stock

₹65,963 (-65.96%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Pyxis Oncology Stock

29%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Pyxis Oncology Stock from India on INDmoney has increased by 29% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Pyxis Oncology, Inc.

  • Name

    Holdings %

  • Pfizer Inc

    11.34%

  • LAURION CAPITAL MANAGEMENT LP

    5.85%

  • BlackRock Inc

    5.28%

  • TANG CAPITAL MANAGEMENT LLC

    4.03%

  • Millennium Management LLC

    4.01%

  • Vanguard Group Inc

    3.47%

Analyst Recommendation on Pyxis Oncology Stock

Rating
Trend

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 13 Wall street analysts offering stock ratings for Pyxis Oncology(by analysts ranked 0 to 5 stars)

Pyxis Oncology Share Price Target

What analysts predicted

Upside of 380.62%

Target:

$6.20

Current:

$1.29

Pyxis Oncology share price target is $6.20, a slight Upside of 380.62% compared to current price of $1.29 as per analysts' prediction.

Pyxis Oncology Stock Insights

  • Price Movement

    In the last 1 year, PYXS stock has moved down by -65.7%
  • PYXS vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 135.6%
  • PYXS vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 162.8%
  • Price to Sales

    ForPYXS every $1 of sales, investors are willing to pay $28.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Pyxis Oncology Technicals Summary

Sell

Neutral

Buy

Pyxis Oncology is currently in a neutral trading position according to technical analysis indicators.

Pyxis Oncology, Inc. Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Pyxis Oncology, Inc. logo
18.18%
17.12%
-62.21%
-50.57%
-90.15%
Regeneron Pharmaceuticals, Inc. logo
6.48%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
1.77%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-14.45%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
13.79%
83.28%
75.87%
111.28%
242.25%

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Organization
Pyxis Oncology
Employees
44
CEO
Dr. Lara S. Sullivan M.D., MBA
Industry
Services

Key Management of Pyxis Oncology, Inc.

NameTitle
Dr. Lara S. Sullivan M.D., MBA
CEO, President, Chief Medical Officer & Director
Dr. Balu N. Balasubramanian Ph.D.
Interim Chief Technology Officer
Dr. Jan Pinkas Ph.D.
Chief Scientific Officer
Dr. Charles T. Gombar Ph.D.
Senior Vice President of Portfolio & Program Management
Mr. Stephen T. Worsley MBA
Senior VP & Chief Business Officer
Dr. Michael Bui
Head of Global Regulatory Affairs
Dr. Supriya Roth Ph.D.
Head of Commercial Development
Dr. Shui He Ph.D.
Head of Biometrics
Dr. Hongwei Wang M.D., Ph.D.
Head of ADC Development & Clinical Strategy
Ms. Marsha Crochiere Ph.D.
Head of Translational Medicine & Research

Important FAQs about investing in PYXS Stock from India :

What is Pyxis Oncology share price today?

Pyxis Oncology share price today is $1.29 as on at the close of the market. Pyxis Oncology share today touched a day high of $1.33 and a low of $1.29.

What is the 52 week high and 52 week low for Pyxis Oncology share?

Pyxis Oncology share touched a 52 week high of $5.39 and a 52 week low of $0.83. Pyxis Oncology stock price today i.e. is closed at $1.29, lower by 76.07% versus the 52 week high.

How to invest in Pyxis Oncology Stock (PYXS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Pyxis Oncology on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Pyxis Oncology Shares that will get you 1.1628 shares as per Pyxis Oncology share price of $1.29 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Pyxis Oncology Stock (PYXS) from India?

Indian investors can start investing in Pyxis Oncology (PYXS) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Pyxis Oncology stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Pyxis Oncology share’s latest price of $1.29 as on August 30, 2025 at 1:29 am IST, you will get 7.7519 shares of Pyxis Oncology. Learn more about fractional shares .

What are the returns that Pyxis Oncology has given to Indian investors in the last 5 years?

Pyxis Oncology stock has given -90.15% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?